Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
Japan: These 73 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Japan: These 73 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Japan Patent 2,009,504,709
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Japan Patent 5,284,092
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Japan Patent 5,452,918
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can BRILINTA (ticagrelor) generic drug versions launch in Japan?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: Japan Patent 2,014,040,448
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can BRILINTA (ticagrelor) generic drug versions launch in Japan?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: Japan Patent 5,385,139
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch in Japan?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 04, 2026
Generic Entry Controlled by: Japan Patent 5,893,083
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAMSCA (tolvaptan) generic drug versions launch in Japan?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 04, 2026
Generic Entry Controlled by: Japan Patent 5,893,083
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can LIVDELZI (seladelpar lysine) generic drug versions launch in Japan?
Generic name: seladelpar lysine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 13, 2026
Generic Entry Controlled by: Japan Patent 2,009,514,797
LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-six countries.
The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.
When can LIVDELZI (seladelpar lysine) generic drug versions launch in Japan?
Generic name: seladelpar lysine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 13, 2026
Generic Entry Controlled by: Japan Patent 5,467,770
LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-six countries.
The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in Japan?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Japan Patent 2,009,509,962
ESBRIET is a drug marketed by Legacy. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in Japan?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Japan Patent 5,715,101
ESBRIET is a drug marketed by Legacy. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in Japan?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Japan Patent 5,837,732
ESBRIET is a drug marketed by Legacy. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch in Japan?
Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Japan Patent 2,009,508,903
ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering ZUNVEYL
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in Japan?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Japan Patent 5,375,611
This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Japan?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Japan Patent 2,009,511,490
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Japan?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Japan Patent 2,013,014,601
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Japan?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Japan Patent 2,014,111,659
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Japan?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Japan Patent 5,129,143
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in Japan?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Japan Patent 5,856,211
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in Japan?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Japan Patent 2,009,513,703
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in Japan?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Japan Patent 5,191,391
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in Japan?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Japan Patent 5,814,903
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in Japan?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Japan Patent 2,009,514,976
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in Japan?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Japan Patent 2,012,246,323
Patent Title: PHARMACEUTICAL SALT AND POLYMORPH OF N- (5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE, FACTOR XA INHIBITOR
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in Japan?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Japan Patent 5,227,178
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in Japan?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Japan Patent 2,008,542,447
This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE
See drug price trends for ENTRESTO SPRINKLE.
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-seven suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Japan?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Japan Patent 2,010,509,358
PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.
This drug has one hundred and eighteen patent family members in twenty-seven countries.
See drug price trends for PYLARIFY.
The generic ingredient in PYLARIFY is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Japan?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Japan Patent 2,010,509,358
PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.
This drug has one hundred and eighteen patent family members in twenty-seven countries.
The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in Japan?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Japan Patent 2,010,509,343
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in Japan?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Japan Patent 2,013,241,447
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in Japan?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Japan Patent 5,244,810
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in Japan?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Japan Patent 6,220,180
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can SOFDRA (sofpironium bromide) generic drug versions launch in Japan?
Generic name: sofpironium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2026
Generic Entry Controlled by: Japan Patent 2,009,515,889
SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.
This drug has one hundred and sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in Japan?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Japan Patent 2,013,064,008
Patent Title: GANAXOLONE FORMULATION AND METHOD FOR PREPARING THE SAME AND USE THEREOF
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug.
This drug has fifty patent family members in sixteen countries. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in Japan?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Japan Patent 5,334,588
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug.
This drug has fifty patent family members in sixteen countries. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in Japan?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Japan Patent 5,748,732
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug.
This drug has fifty patent family members in sixteen countries. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Japan?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Japan Patent 2,013,249,312
Patent Title: NEW NON-ABUSE PHARMACEUTICAL COMPOSITION CONTAINING OPIOID
This drug has sixty-two patent family members in thirty-two countries. There has been litigation on patents covering ZUBSOLV
See drug price trends for ZUBSOLV.
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Japan?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Japan Patent 5,484,062
This drug has sixty-two patent family members in thirty-two countries. There has been litigation on patents covering ZUBSOLV
See drug price trends for ZUBSOLV.
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Japan?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Japan Patent 5,894,239
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in Japan?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Japan Patent 2,010,512,329
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in Japan?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Japan Patent 2,013,144,683
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in Japan?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Japan Patent 5,513,558
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch in Japan?
Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Japan Patent 2,010,512,414
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.
When can BUNAVAIL (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Japan?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 13, 2026
Generic Entry Controlled by: Japan Patent 5,586,151
This drug has eighty-three patent family members in twenty-six countries. There has been litigation on patents covering BUNAVAIL
See drug price trends for BUNAVAIL.
The generic ingredient in BUNAVAIL is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in Japan?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Japan Patent 2,009,519,314
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in Japan?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Japan Patent 2,013,049,715
Patent Title: THERAPEUTIC COMPOSITION
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in Japan?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Japan Patent 5,484,733
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in Japan?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Japan Patent 5,709,826
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Japan?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Japan Patent 2,009,521,462
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Japan?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Japan Patent 5,200,939
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Japan?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Japan Patent 5,790,629
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Japan?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Japan Patent 6,604,739
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can AURYXIA (ferric citrate) generic drug versions launch in Japan?
Generic name: ferric citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 26, 2027
Generic Entry Controlled by: Japan Patent 2,009,525,277
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Japan?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Japan Patent 2,010,517,997
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Japan?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Japan Patent 5,382,723
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can NESINA (alogliptin benzoate) generic drug versions launch in Japan?
Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Japan Patent 2,010,517,936
This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA
See drug price trends for NESINA.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.
When can NESINA (alogliptin benzoate) generic drug versions launch in Japan?
Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Japan Patent 5,284,967
This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA
See drug price trends for NESINA.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Japan?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Japan Patent 2,010,517,937
This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can LEXISCAN (regadenoson) generic drug versions launch in Japan?
Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 02, 2027
Generic Entry Controlled by: Japan Patent 5,326,156
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Japan Patent 2,010,519,217
PANCREAZE is a drug marketed by
This drug has twenty-eight patent family members in eighteen countries.
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Japan Patent 2,014,074,053
PANCREAZE is a drug marketed by
This drug has twenty-eight patent family members in eighteen countries.
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Japan Patent 5,966,202
PANCREAZE is a drug marketed by
This drug has twenty-eight patent family members in eighteen countries.
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Japan Patent 2,010,519,217
ZENPEP is a drug marketed by
This drug has twenty-eight patent family members in eighteen countries.
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Japan Patent 2,014,074,053
ZENPEP is a drug marketed by
This drug has twenty-eight patent family members in eighteen countries.
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Japan?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Japan Patent 5,966,202
ZENPEP is a drug marketed by
This drug has twenty-eight patent family members in eighteen countries.
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch in Japan?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Japan Patent 2,009,530,298
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch in Japan?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Japan Patent 5,479,086
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in Japan?
Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Japan Patent 2,009,530,298
TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering TUZISTRA XR
See drug price trends for TUZISTRA XR.
The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. There are twenty-nine drug master file entries for this API. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.
When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in Japan?
Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Japan Patent 5,479,086
TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering TUZISTRA XR
See drug price trends for TUZISTRA XR.
The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. There are twenty-nine drug master file entries for this API. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.
When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in Japan?
Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: Japan Patent 2,011,037,858
Patent Title: IMIDAZOLOTHIAZOLE COMPOUND FOR TREATING DISEASE
VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.
This drug has one hundred and twenty-seven patent family members in thirty-three countries.
See drug price trends for VANFLYTA.
The generic ingredient in VANFLYTA is quizartinib dihydrochloride. One supplier is listed for this generic product. Additional details are available on the quizartinib dihydrochloride profile page.
When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in Japan?
Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: Japan Patent 4,610,668
VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.
This drug has one hundred and twenty-seven patent family members in thirty-three countries.
See drug price trends for VANFLYTA.
The generic ingredient in VANFLYTA is quizartinib dihydrochloride. One supplier is listed for this generic product. Additional details are available on the quizartinib dihydrochloride profile page.
When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in Japan?
Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Japan Patent 2,009,530,385
This drug has sixty-two patent family members in twenty-four countries. There has been litigation on patents covering SPRAVATO
See drug price trends for SPRAVATO.
The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this generic product. Additional details are available on the esketamine hydrochloride profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in Japan?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Japan Patent 2,010,522,143
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in Japan?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Japan Patent 2,014,159,416
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in Japan?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Japan Patent 5,893,651
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Japan?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Japan Patent 2,010,522,173
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Japan?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Japan Patent 5,442,459
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Japan?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Japan Patent 6,041,919
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Japan?
Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Japan Patent 2,010,522,692
This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI
See drug price trends for EDARBI.
The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.
When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Japan?
Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Japan Patent 5,283,632
This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI
See drug price trends for EDARBI.
The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.
When can BYSANTI (milsaperidone) generic drug versions launch in Japan?
Generic name: milsaperidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Japan Patent 2,010,522,773
BYSANTI is a drug marketed by Vanda Pharms Inc. There are ten patents protecting this drug.
This drug has sixty-one patent family members in twelve countries. There has been litigation on patents covering BYSANTI
The generic ingredient in BYSANTI is milsaperidone. One supplier is listed for this generic product. Additional details are available on the milsaperidone profile page.
When can BYSANTI (milsaperidone) generic drug versions launch in Japan?
Generic name: milsaperidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Japan Patent 5,586,094
BYSANTI is a drug marketed by Vanda Pharms Inc. There are ten patents protecting this drug.
This drug has sixty-one patent family members in twelve countries. There has been litigation on patents covering BYSANTI
The generic ingredient in BYSANTI is milsaperidone. One supplier is listed for this generic product. Additional details are available on the milsaperidone profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Japan?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: Japan Patent 2,009,532,472
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.